Pegaptanib
- Generic Name
- Pegaptanib
- Drug Type
- Biotech
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00820742
Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 5
- Registration Number
- NCT00790803
- Locations
- 🇺🇸
Wake Forest University Eye Center, Winston-Salem, North Carolina, United States
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
- Conditions
- Age-related Macular Degeneration
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- Klinikum Ludwigshafen
- Target Recruit Count
- 10
- Registration Number
- NCT00788177
- Locations
- 🇩🇪
Department of Ophthalmology, Ludwigshafen hospital, Ludwigshafen, Germany
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
- Conditions
- Macular Edema Associated With Diabetes Mellitus
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT00605280
- Locations
- 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00549055
- Locations
- 🇧🇪
Pfizer Investigational Site, Liege, Belgium
MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen
- Conditions
- Macular Degeneration
- Interventions
- Drug: intravitreal injection of Bevacizumab (Avastin)
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Target Recruit Count
- 60
- Registration Number
- NCT00531336
- Locations
- 🇦🇹
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Vienna, Austria
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 501
- Registration Number
- NCT00460408
- Locations
- 🇸🇪
Pfizer Investigational Site, Västerås, Sweden
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Palmetto Retina Center, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00406107
- Locations
- 🇺🇸
Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸Cumberland Valley Retina Center, Hagerstown, Maryland, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States
The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 1
- Registration Number
- NCT00358423
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
- Conditions
- Age-Related Macular Degeneration (AMD)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT00354445
- Locations
- 🇺🇸
Retina Research Institute of Texas, LLC, Abilene, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.